Literature DB >> 14742551

Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation.

Drew M Catron1, Yvonne Lange, Jayme Borensztajn, Matthew D Sylvester, Bradley D Jones, Kasturi Haldar.   

Abstract

We have previously shown that Salmonella enterica serovar Typhimurium infection perturbs the host cholesterol biosynthetic pathway. Here we show that inhibiting the first step of this pathway (3-hydroxy-3-methylglutaryl coenzyme A reductase) reduces the growth of intracellular S. enterica serovar Typhimurium and has no effect on extracellular bacterial growth. Selectively inhibiting synthesis of downstream sterol components has no effect on infection, suggesting that the effect of statins on host nonsterol intermediates is detrimental to bacterial growth. Furthermore, statins also reduce bacterial proliferation in the S. enterica serovar Typhimurium mouse model. This suggests that blocking the production of nonsterol precursors in the host cell can be used to reduce infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742551      PMCID: PMC321618          DOI: 10.1128/IAI.72.2.1036-1042.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Live Salmonella modulate expression of Rab proteins to persist in a specialized compartment and escape transport to lysosomes.

Authors:  S Hashim; K Mukherjee; M Raje; S K Basu; A Mukhopadhyay
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

Review 2.  Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.

Authors:  F Bernini; A Poli; R Paoletti
Journal:  Cardiovasc Drugs Ther       Date:  2001       Impact factor: 3.727

3.  Intracellular replication of Salmonella typhimurium strains in specific subsets of splenic macrophages in vivo.

Authors:  S P Salcedo; M Noursadeghi; J Cohen; D W Holden
Journal:  Cell Microbiol       Date:  2001-09       Impact factor: 3.715

4.  Salmonella pathogenicity island 2-encoded type III secretion system mediates exclusion of NADPH oxidase assembly from the phagosomal membrane.

Authors:  A Gallois; J R Klein; L A Allen; B D Jones; W M Nauseef
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Salmonella pathogenicity island 2-dependent macrophage death is mediated in part by the host cysteine protease caspase-1.

Authors:  D M Monack; C S Detweiler; S Falkow
Journal:  Cell Microbiol       Date:  2001-12       Impact factor: 3.715

6.  The effect of statins on mortality in patients with bacteremia.

Authors:  A P Liappis; V L Kan; C G Rochester; G L Simon
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

7.  Salmonella maintains the integrity of its intracellular vacuole through the action of SifA.

Authors:  C R Beuzón; S Méresse; K E Unsworth; J Ruíz-Albert; S Garvis; S R Waterman; T A Ryder; E Boucrot; D W Holden
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

8.  Complete genome sequence of Salmonella enterica serovar Typhimurium LT2.

Authors:  M McClelland; K E Sanderson; J Spieth; S W Clifton; P Latreille; L Courtney; S Porwollik; J Ali; M Dante; F Du; S Hou; D Layman; S Leonard; C Nguyen; K Scott; A Holmes; N Grewal; E Mulvaney; E Ryan; H Sun; L Florea; W Miller; T Stoneking; M Nhan; R Waterston; R K Wilson
Journal:  Nature       Date:  2001-10-25       Impact factor: 49.962

9.  Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

Authors:  U Laufs; M Endres; F Custodis; K Gertz; G Nickenig; J K Liao; M Böhm
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

10.  Pleiotropic effects of statins in atherosclerosis and diabetes.

Authors:  S Bellosta; N Ferri; L Arnaboldi; F Bernini; R Paoletti; A Corsini
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

View more
  41 in total

1.  Statins enhance formation of phagocyte extracellular traps.

Authors:  Ohn A Chow; Maren von Köckritz-Blickwede; A Taylor Bright; Mary E Hensler; Annelies S Zinkernagel; Anna L Cogen; Richard L Gallo; Marc Monestier; Yanming Wang; Christopher K Glass; Victor Nizet
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

Review 2.  Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells.

Authors:  P Goluszko; B Nowicki
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo.

Authors:  Sanchita Bhatnagar; Kazuhiko Shinagawa; Francis J Castellino; Jeffrey S Schorey
Journal:  Blood       Date:  2007-07-31       Impact factor: 22.113

4.  Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.

Authors:  Bruno Pradines; Marylin Torrentino-Madamet; Albin Fontaine; Maud Henry; Eric Baret; Joel Mosnier; Sébastien Briolant; Thierry Fusai; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

5.  Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.

Authors:  Rina P M Wong; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

6.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

Review 7.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

8.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

9.  Lovastatin protects against experimental plague in mice.

Authors:  Saravanan Ayyadurai; Hubert Lepidi; Claude Nappez; Didier Raoult; Michel Drancourt
Journal:  PLoS One       Date:  2010-06-02       Impact factor: 3.240

10.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.